Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1912 plus R-GemOx versus R-GemOx in relapsed/refractory diffuse large B-cell lymphoma
CTR20251332Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-A1912 in diffuse large B-cell lymphoma (DLBCL), sponsored by Hengrui Therapeutics. Started May 2025; status: active.
02
Drugs
SHR-A1912
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20251332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251332.